

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 25

OMB APPROVAL

OMB Number: 3235-0080
Expires: March 31, 2018
Estimated average burden
hours per response: 1.7

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number [333-250986](#)

Issuer: [4D Pharma PLC](#)

Exchange: Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address: 5th Floor, 9 Bond Court
Leeds UNITED KINGDOM LS1 2JZ

Telephone number: 44-113-895-0130

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

American depositary shares and warrant

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

☐ 17 CFR 240.12d2-2(a)(1)

☐ 17 CFR 240.12d2-2(a)(2)

☐ 17 CFR 240.12d2-2(a)(3)

☐ 17 CFR 240.12d2-2(a)(4)

☒ Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

☐ Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements for the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

<u>2022-07-19</u>	By <u>Aravind Menon</u>	<u>Hearings Advisor</u>
Date	Name	Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. [See](#) General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Delisting Determination, The Nasdaq Stock Market, LLC,
July 19, 2022, 4D pharma plc. The Nasdaq Stock Market LLC
(the Exchange) has determined to remove from listing
the American depositary shares and warrant of 4D pharma plc,
effective at the opening of the trading session on July 29, 2022.
Based on review of information provided by the Company, Nasdaq Staff
determined that the Company no longer qualified for listing on the
Exchange pursuant to Listing Rules 5101, 5110(b), and IM-5101-1.
The Company was notified of the Staff determination on
June 27, 2022. The Company did not appeal the Staff
determination to the Hearings Panel. The Listing Council
did not call the matter for review. The Staff determination
to delist the Company common stock became final on
July 7, 2022.